Download from app store
We have detected that you are using an Ad Blocker.
PracticeUpdate is free to end users but we rely on advertising to fund our site. Please consider supporting PracticeUpdate by whitelisting us in your ad blocker.
We have sent a message to the email address you have provided, . If this email is not correct, please update your settings with your correct address.
The email address you provided during registration, , does not appear to be valid. Please update your settings with a valid address before to continue using PracticeUpdate.
Please provide your AHPRA Number to ensure that you are given the correct level of access to our site.
featured
Published in Neurology

Journal Scan / Research · September 04, 2024

Apixaban vs Aspirin in Patients With Cancer and Cryptogenic Stroke

JAMA Neurology

 

Additional Info

Disclosure statements are available on the authors' profiles:

JAMA Neurology
Apixaban vs Aspirin in Patients With Cancer and Cryptogenic Stroke: A Post Hoc Analysis of the ARCADIA Randomized Clinical Trial
JAMA Neurol 2024 Aug 12;[EPub Ahead of Print], BB Navi, C Zhang, B Miller, M Cushman, SE Kasner, MSV Elkind, DL Tirschwell, WT Longstreth, RA Kronmal, M Beyeler, J Elm, RM Zweifler, J Tarsia, CW Cereda, G Bianco, G Costamagna, P Michel, JP Broderick, DJ Gladstone, H Kamel, C Streib

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.

Further Reading